title: [Research and development of beraprost sodium, a new stable PGI2 analogue].
abstract: A novel prostaglandin I2 (PGI2) analogue, beraprost sodium, is the first launched drug as an orally active PGI2. PGI2 was discovered in 1976, and has attracted much attention as a medicine for cardiovascular diseases such as strokes and heart attacks because of its potent antiplatelet and vasodilating effect. However, PGI2 is extremely unstable for the use as practical medicines. Thus, stable PGI2 analogues have been explored by a large number of researchers in the world. Just after the discovery of PGI2, we started a research on chemically and metabolically stable PGI2 derivatives with longer duration of action and less adverse reaction. We invented a novel class of stable PGI2, 5,6,7-trinor-4,8-inter-m-phenylenePGI2 analogues that have the phenol moiety instead of the enolether moiety of PGI2. Further efforts were devoted to enhance the efficacy of the PGI2 analogues and to eliminate their side effects, and an orally active analogue, beraprost sodium, was obtained. In order to establish the synthetic route of beraprost sodium, various novel processes were invented, including ortho-selective metalation of bromoanisoles by means of Grignard reagents, copper-catalyzed SN2' cyclization to prepare cyclopenta[b]benzofuran, and stereo-selective elongation of the omega-side chain by Prins reaction. Beraprost sodium inhibit platelet aggregation induced by adenosine 5'-diphosphate (ADP), collagen and arachidonic acid. It was shown that the drug has a potent antiplatelet effect both in vitro and ex vivo in human and several animal species. In clinical studies, beraprost sodium exerted a marked effect to improve arteriosclerosis obliterans. No serious adverse effects related with the drug have been reported. It was highly evaluated as an orally active PGI2 by pharmaceutical companies overseas as well, and now clinical trials are under way in U.S.A. and Europe.
authors.affiliation: Basic Research Laboratories, Toray Industries, Inc., Kanagawa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nishio
authors.forename: H
authors.initials: H
authors.lastname: Nagase
authors.forename: K
authors.initials: K
authors.lastname: Kanou
authors.forename: S
authors.initials: S
authors.lastname: Aoki
authors.forename: Y
authors.initials: Y
authors.lastname: Kanbayashi
mesh_terms: D000818:Animals; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D014665:Vasodilator Agents / Q000138:chemical synthesis / Q000494:pharmacology
chemical_list: D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; C048081:beraprost; D011464:Epoprostenol